A £750,000 ($1 million) global collaboration has been launched to advance next-generation vaccine technology. iiDiagnostics (iiDX), a company formed by the Infection Innovation Consortium: iiCON, and Canadian biotech Eyam Health have launched a collaboration to bring forward Eyam Health’s novel vaccine technology using advanced automated organoid models. This £750,000 ($1 million) international initiative will combine Eyam’s advanced vaccine design and delivery platforms with world-leading automated […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!